A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.
ASJC Scopus subject areas
- Pharmacology (medical)